Brought to you by 
Kemia closes $33.5mm Series B round
26 Oct 2012
Executive Summary
Kemia, a biotech active in the discovery and development of diverse oral small-molecule drug candidates, closed a $33.5mm Series B financing led by JP Morgan Partners. New investors were Novo AS and Hamilton Apex Technology. All Series A investors returned: Alta Partners, Forward Ventures, Texas Pacific Group, TPG Ventures, and Novartis BioVentures.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Kemia closes $33.5mm Series B round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice